AGP Picks
View all

AGP Executive Report

Your go-to archive of top headlines, summarized for quick and easy reading.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

Ebola: A Swiss woman treated in Geneva has recovered and was discharged on November 11. The wider outbreak in the Democratic Republic of the Congo remains severe, with more than 11,100 cases and 5,400 deaths; WHO says hundreds of new cases are still being reported weekly. Swiss Drug Research: Neurosterix, spun out of Swiss biotech Addex, raised $105 million to advance an experimental schizophrenia treatment toward Phase 2 testing. Food Safety: Pork products have been linked to a rise in hepatitis E cases in Switzerland. Drug Detection: Researchers in Switzerland have developed a method to improve detection of GHB, the drug used in some drink-spiking assaults. Heat and Health: Switzerland’s summer broke the 2003 heat record, with an estimated 1,257 heat-related deaths.

Drug-Facilitated Assault: A new Swiss method may help detect GHB, a date-rape drug, for longer after exposure. Swiss Biopharma: Lonza plans to buy five US drug-manufacturing sites from Merck KGaA, expanding production capacity for complex medicines and gene therapies; the deal would transfer about 1,100 employees if completed. Schizophrenia Research: Geneva-based Addex’s spinout Neurosterix raised $105 million to support planned Phase 2 trials of a potential treatment. Heat and Health: Switzerland’s record-breaking summer was linked to an estimated 1,257 heat-related deaths.

Forensic Medicine: University of Zurich researchers found a urine marker that can detect GHB, often used to incapacitate victims, for up to 72 hours—far longer than standard tests. The finding could give sexual-assault investigations more time to identify suspected drugging. Heat Risk: Switzerland’s record-breaking summer of 2003 was linked to an estimated 1,257 heat-related deaths, underscoring the toll of extreme temperatures. Heart Health: A trial involving researchers at the University of Bern found that stopping statins may carry little added risk for some adults over 70 in the short term, but raised longer-term concerns; treatment decisions should be made with a clinician. Rare Tumours: Pimjetmi, a treatment for some adults with symptomatic tenosynovial giant cell tumour, won U.S. approval. It was already approved in Switzerland, Canada and China.

Swiss Forensic Research: A University of Zurich-led team is testing a biomarker that may help detect GHB, a drug used in assaults, for up to three days—far longer than standard tests. Researchers examined 2,414 urine samples from real forensic cases. Ebola Outbreak: The outbreak in the Democratic Republic of the Congo has reached 5,306 confirmed deaths. Fighting has disrupted health response efforts, including contact tracing. Novartis Safety Review: U.S. authorities are investigating possible tumors in children treated with the Swiss drugmaker’s gene therapy Zolgensma; Novartis has reported nine cases. Assisted Suicide Debate: A former British soldier with PTSD died at a Swiss clinic after, his family says, years of struggling to get adequate care in the UK.

Drug Safety: U.S. authorities are investigating tumor reports in children treated with Novartis’s Zolgensma gene therapy; the company has reported nine cases, renewing scrutiny of a treatment for spinal muscular atrophy. Assisted Dying and Care: A British former soldier with PTSD died by assisted suicide at a Swiss clinic after years of unmet treatment needs, raising concerns about gaps in care and end-of-life safeguards. Wellness Research: A Swiss study reported that regular cold showers were linked to 31% fewer sick days, though the finding is not a guarantee of protection. Ebola Outbreak: The Democratic Republic of Congo is facing its largest Ebola outbreak on record, with more than 10,000 cases and 5,198 deaths reported by WHO. Heat and Health: A summer heatwave was linked to more than 1,200 deaths in Switzerland, highlighting the health toll of extreme temperatures.

Blood Cancer Treatment: A new licensing deal gives Avanzanite rights to bring Zemcelpro, a cord-blood stem-cell therapy for some adults with blood cancers, to Switzerland and 31 other European markets. Statins in Older Adults: A Swiss-led trial found that stopping statins in adults over 70 met its two-year safety benchmark, but heart attacks, strokes or deaths were more frequent among those who stopped. Researchers say the findings do not justify a general recommendation to quit. Mental Health: Swiss tennis player Leandro Riedi has spoken about a suicide attempt in 2024, saying he hopes sharing his experience will help others struggling with anxiety and panic attacks. Gene Therapy Safety: The US FDA is investigating reports of tumours in children treated with Novartis’s Zolgensma. Novartis has reported nine cases; a causal link has not been established.

Cell Therapy Access: A new licensing deal gives Avanzanite rights to commercialize Zemcelpro, a cord-blood stem-cell treatment for adults with blood cancers, in Switzerland and 31 other European countries. Mental Health: Swiss tennis player Leandro Riedi has revealed he attempted suicide in 2024, speaking out to encourage greater attention to anxiety and mental health. Gene Editing: Swiss-based CRISPR Therapeutics reported early trial results showing its one-time treatment lowered triglycerides by an average of 63% after 30 days in people with dangerously high levels; larger studies are needed. Poverty and Health: Switzerland’s new poverty council, representing people with lived experience, has made health and access to services among its priorities. Gene Therapy Safety: The US FDA is investigating possible tumour risks after Novartis’s Zolgensma treatment; the company has reported nine tumour cases in children, but a causal link has not been established. Heat and Health: A Swiss estimate links last summer’s heat to nearly 1,260 deaths, underscoring the toll of extreme temperatures.

Rare-Disease Treatment: Avanzanite has secured European commercial rights to Zemcelpro, a stem-cell therapy for some adults with blood cancers who need a transplant and lack a suitable donor. The company plans to seek Swiss authorization. Statins in Older Adults: A Swiss-led trial found stopping statins was no worse than continuing them over two years for adults 70 and older with multiple conditions but no prior cardiovascular disease. Longer follow-up showed a higher risk of cardiovascular events in the group that stopped, supporting individualized decisions with a doctor. Gene-Therapy Safety: Novartis reported nine cases of tumors in children treated with Zolgensma, prompting an FDA investigation. The reports have raised safety concerns but do not establish that the treatment caused the tumors. Cold Showers: A University of Basel study of 719 adults found participants assigned to cold showers reported fewer illness days and work absences. The results suggest a possible benefit, but do not prove cold showers prevent illness. Online Medicine Safety: A study of Google results across 30 European countries found more than one in three medicine-vendor links led to sellers lacking recognized authorization, with illicit vendors especially common for controlled drugs.

Autoimmune Treatment: Swiss-based CRISPR Therapeutics reported early results for its experimental gene-edited CAR-T therapy: all nine patients with inflammatory myopathy improved, while five of six systemic-sclerosis patients responded at three months. The 21-patient trial is still small, and the company reported no severe immune complications. Gene Therapy Safety: The FDA is investigating tumors reported after Novartis’s Zolgensma treatment for spinal muscular atrophy. Nine cases have been reported since 2019; in two, treatment-related DNA was found in tumor cells. Ebola Outbreak: The WHO says the DRC outbreak has reached 10,668 cases and 5,198 deaths. Switzerland and the UK have evacuated infected citizens; the agency warns that transmission remains high. Heat and Health: A report says last summer’s heatwave was linked to more than 1,200 deaths in Switzerland, underscoring the toll of extreme temperatures. Health Costs: A report warns that US drug-pricing policies could push up Swiss health-insurance premiums.

Ebola Alert: The DRC’s outbreak has reached 10,668 cases and 5,198 deaths, with transmission active in 51 health zones. WHO says Switzerland evacuated a citizen infected with the virus and warns that many deaths, especially among children, are occurring in communities. Swiss Research: University of Zurich researchers found that support cells can help repair damaged brain tissue in mice, with similar cells observed in human samples. ETH Zurich scientists have also developed an experimental implant that lowered blood sugar in diabetic mice; human trials are still years away. Drug Safety: Novartis reported nine cases of tumours in children treated with its gene therapy Zolgensma, prompting an FDA investigation into a possible risk. Health in Switzerland: A report says the number of people living with cancer in Switzerland has doubled over two decades; separate analysis estimates last summer’s heatwave contributed to more than 1,200 deaths.

Ebola outbreak: WHO reports 10,668 cases and 5,198 deaths in the DRC, with transmission continuing across eight provinces. Switzerland has medically evacuated a confirmed case involving one of its citizens. Gene therapy safety: The US FDA is investigating a possible tumour risk linked to Novartis’s Zolgensma. The company has received nine tumour reports among treated patients; regulators say the therapy’s benefits still outweigh known risks. Heat-related deaths: Last summer’s heatwave was linked to nearly 1,260 deaths in Switzerland, underscoring the health toll of extreme heat. Cancer in Switzerland: The number of people living with cancer has doubled in 20 years. Diabetes research: ETH Zurich scientists have developed an experimental implant that lowered blood sugar in diabetic mice by converting excess glucose; human trials are still years away.

Gene-therapy Safety: Novartis says nine children treated with its spinal muscular atrophy therapy Zolgensma developed tumors; in two cases, the viral vector showed signs of entering patients’ DNA. The company has notified health authorities. Swiss Dental Innovation: Zug-based vVardis is seeking a US IPO valuation of up to $4.37 billion for its non-invasive treatment for early tooth decay. Summer Heat Toll: A new report links last summer’s heatwave to nearly 1,260 deaths in Switzerland, underscoring the health risks of extreme temperatures. Chikungunya Watch: Swiss patients with chikungunya were reported to live close to one another, raising questions about where infections occurred. Digital Health Habits: Four in ten people in Switzerland reportedly use AI to assess their symptoms, highlighting the growing role of chatbots in self-diagnosis. Hospital Workers’ Rights: The European Court of Human Rights criticized Switzerland over a ruling that made hospital strikes illegal.

Gene Therapy Safety: Novartis says nine children treated with its spinal muscular atrophy therapy Zolgensma have developed tumors. Two cases showed signs that the therapy’s viral vector had integrated into patients’ DNA; both children have received treatment and remain under monitoring. Heat Risk: Summer heat was linked to nearly 1,260 deaths in Switzerland, underscoring the toll of extreme temperatures on public health. Hospital Rights: The European Court of Human Rights criticized Switzerland over a ruling that made hospital strikes illegal, putting healthcare workers’ labor rights under scrutiny. Digital Health: A Swiss survey found that four in ten people use AI to assess their own health, raising questions about the reliability of online self-diagnosis.

Heat Health: Switzerland’s hottest summer on record is estimated to have caused about 1,257 deaths from May to August — 5.5% of all deaths during those months. Around 85% of victims were over 75, and the toll could rise once September is included. Cancer: The number of people living with cancer in Switzerland has doubled over the past 20 years, highlighting the growing need for long-term care and support. Ebola Care: A patient infected with Ebola in Nigeria was transferred to Geneva University Hospital for specialist treatment; her husband has since been discharged. Hospital Rights: The European Court of Human Rights criticized Switzerland’s ruling that hospital strikes were illegal, raising questions about healthcare workers’ right to take industrial action. Cancer Research: Zurich-based Molecular Partners reported promising preclinical results for an experimental cancer therapy designed to target tumors while sparing healthy tissue.

Hospital Rights: The European Court of Human Rights ruled that Switzerland violated the right to strike in a case involving former La Providence Hospital employees, finding they could not reasonably foresee that their initially lawful action would later be deemed unlawful. Swiss Research: Topadur’s Swiss-led Phase 2a trial of a topical treatment for systemic sclerosis-related digital ulcers is moving to higher dose levels after its safety review found no serious drug reactions. Public Health: A report says chikungunya patients in Switzerland live close to one another; meanwhile, the Ebola outbreak in Central Africa continues to spread, with a Swiss patient previously evacuated to Geneva for care. Care and Disease: Switzerland will cover medical expenses for Italian victims of the Crans-Montana fire. A separate report says the number of people living with cancer in Switzerland has doubled over two decades. Pharma Sector: An industry index warns that Swiss drugmakers are lagging in technology and clinical trials.

Crans-Montana Care Costs: Switzerland will cover about CHF1.5 million in hospital bills for 12 Italian victims of the hotel fire, easing pressure on grieving families and relations with Rome. Cancer Burden: The number of people living with cancer in Switzerland has doubled over the past 20 years. Digital Health: Four in ten Swiss people reportedly use AI to self-diagnose, raising questions about how they judge online health advice. Food Safety: A wave of cheese recalls in Switzerland has prompted questions about health warnings and consumer safety. Infectious Diseases: Tiger mosquitoes have spread to Switzerland as well as other European countries, raising concern about dengue, chikungunya and Zika; climate change is also reshaping Europe’s disease map. Health Innovation: A new index says Switzerland’s pharma industry is lagging in technology and clinical trials, while the country faces pressure from US drug-pricing policy.

Youth Health: WHO says one in four teenagers worldwide had no active days in the previous week, warning that inactivity raises the risk of heart disease, diabetes and some cancers. Ebola Response: WHO experts have recommended adding two vaccine candidates to trials against the Bundibugyo strain behind the deadly outbreak in the Democratic Republic of Congo. Swiss Research: ETH Zurich researchers report a wireless implant lowered blood sugar in mice using electrical current, while a separate portable breath device can detect fat metabolism; both remain early-stage technologies. Climate and Health: WHO says six practical measures, including heat warnings and safer water systems, could prevent nearly 1.6 million deaths a year. Swiss Health: The number of people living with cancer in Switzerland has doubled over two decades. Switzerland will also cover CHF1.5 million in medical costs for Italian victims of the Crans-Montana fire, waiving reimbursement after 12 patients were treated in Swiss hospitals.

Prevention Cuts: Switzerland’s Federal Office of Public Health must save CHF 11 million a year, prompting cuts to prevention work. Some vaccination information sheets have gone years without updates; experts warn the pullback is short-sighted. Pediatric Sleep: Swiss drugmaker Idorsia says the US FDA has granted breakthrough designation to daridorexant for insomnia in 10- to 17-year-olds. The designation is not an approval; a Phase 2 trial found dose-related improvements in sleep time. Health Costs: Swiss workers’ wages are forecast to rise just 1% in 2027, while health insurance premiums are expected to climb 5%, eroding much of the gain. Digital Health: A recent report says four in ten Swiss people use AI to self-diagnose, raising questions about how reliably people can assess symptoms online. Cold Showers: A Swiss study of 719 adults linked regular cold showers with 31% fewer sick days over 12 weeks, but the results were self-reported and do not prove cold showers prevent illness.

Digital Health: 42% of Swiss people now use AI chatbots to check health symptoms, up from 20% a year ago, a CSS study found. Researchers say chatbots are an added source of information, not a substitute for doctors. Swiss Biopharma: Lonza will acquire five US manufacturing sites from Merck, more than doubling its US footprint and adding capacity for cancer and gene therapies. Pain Relief: A University Hospital Zurich study of more than 200 patients found that listening to favourite music eased pain during IV insertion more than Mozart or relaxation music. Heart Research: A Swiss hospital study linked competitive athletics in patients with a rare form of cardiomyopathy to more abnormal ECG findings and a higher unadjusted risk of serious outcomes. Injury and Recovery: Olympic champion Michelle Gisin has retired after a serious training crash led to neck, knee and wrist injuries. Cold Showers: A Swiss study found participants who took mostly cold showers reported fewer sick days, but the groups were not randomly assigned and results were self-reported—so the finding does not show that cold showers prevent illness.

Swiss Diagnostics: Roche secured US clearance for its cobas eplex respiratory pathogen panel and a European CE mark for its cobas smart e analyzer, while also expanding its cancer-diagnostic portfolio with a mesothelioma test. Ebola Watch: A Swiss woman treated for Ebola was evacuated from Nigeria to Geneva University Hospitals and was reported stable. Nigeria’s 62 identified contacts have so far tested negative, with monitoring due to end November 13; the wider outbreak has killed more than 5,300 people, mostly in the Democratic Republic of Congo. Swiss Pharma: Novartis’ heart-drug trial setback has left researchers seeking further support for a genetic cholesterol target. Heat Preparedness: Switzerland’s climate adaptation plan faces criticism after a record-hot summer, sharpening questions about readiness for heat-related health risks.

Sign up for:

Switzerland Health Monitor

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Switzerland Health Monitor

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.